Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06365840
PHASE2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Sponsor: ImmuneOncia Therapeutics Inc.

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.

Official title: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-01-13

Completion Date

2029-08

Last Updated

2025-06-18

Healthy Volunteers

No

Interventions

DRUG

IMC-001

All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.

Locations (1)

Samsung Medical Center

Seoul, South Korea